| CAS NO: | 1638338-43-8 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 生物活性 | Navicixizumab (OMP-305B83) is a bispecific anti-VEGFand anti-DLL4inhibitory antibody. Navicixizumab can combine withPaclitaxel(HY-B0015) forcancerresearch. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tubecancer[1][2][3]. |
| IC50& Target | IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM) |
| 体外研究 (In Vitro) | Navicixizumab (0-100 μM) 在 hVEGF 存在的情况下减少人内皮细胞的增殖[3]. |
| 体内研究 (In Vivo) | Navicixizumab (15 mg/kg，每周一次，持续 4 周) 抑制结肠异种移植肿瘤的生长[3]。 |
| CAS 号 | 1638338-43-8 |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com